Sinovac Biotech, a developer and provider of vaccines in China, has received a certificate of approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico.

Sinovac Biotech, a Chinese provider of biopharmaceutical products, has signed an agreement with Boryung Pharmaceutical Company, a Korean manufacturer of pharmaceuticals, to collaborate on marketing efforts and possible H1N1 vaccine supply to the South Korean government.

Shanghai based industrial gas provider Praxair China has signed a contract with Hebei Baiqi Pharmaceutical Company to supply nitrogen for its pharmaceutical production requirements.

Shandong-based China Biologic Products, a leading plasma-related pharmaceutical company in China, has announced that one of its research projects, "High-Purity Human Albumin," will be listed in the National Torch Plan of China.

U.S. listed Genesis Pharmaceuticals Enterprises,a pharmaceutical company with its principal operations in China, has announced that an American Arbitration Association arbitration panel rejected requests by Capital Research Group, Inc. to award it USD13.8 million and Capital Research Group Partners, Inc. to award it USD13.7 million in a joint arbitration proceeding against Genesis alleging the breach [...]

Sweden-based Orexo and the Chinese pharmaceutical company NovaMed Pharmaceuticals have signed an exclusive licensing and distribution agreement that grants NovaMed rights to seek approval for the marketing and distributing of Abstral Orexo´s product for treatment of breakthrough cancer pain in mainland China and, if granted, to market and sell the product in that market.

Image Solutions, a provider of software and services for the life sciences industry, has announced that its Tianjin, office was granted ISO 27001:2005 certification by the International Organization for Standardization.

Chengdu-based Tianyin Pharmaceutical has received the production license of Tongbianling Capsules in dosage form of 0.25 gram per capsule and is due to market the new product in February 2009.

Harbin based China Sky One Medical, a pharmaceutical company producing over-the-counter drugs in the China recently obtained production approval from the Chinese State Food and Drug Administration for two of its newly developed drugs.

Haikou based China Pharma Holdings,has received approval from China's State Food and Drug Administration to start clinical trials of a combination of an antibiotic with a bacterial-enzyme inhibitor.